Swords R - Search Results

1

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F. Kreitman RJ, et al. Among authors: swords r. Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20. Leukemia. 2018. PMID: 30030507 Free PMC article.

2

Hairy cell leukemia.

Swords R, Giles F. Swords R, et al. Med Oncol. 2007;24(1):7-15. doi: 10.1007/BF02685898. Med Oncol. 2007. PMID: 17673807 Review.

3

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE. Giles FJ, et al. Among authors: swords rt. Leukemia. 2013 Jan;27(1):113-7. doi: 10.1038/leu.2012.186. Epub 2012 Jul 9. Leukemia. 2013. PMID: 22772060 Clinical Trial.

4

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.

Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ, Yang X, Zhou Y, Platzbecker U, Steensma DP, Wolff JE, Fenaux P. Garcia JS, et al. Leuk Res. 2021 May;104:106555. doi: 10.1016/j.leukres.2021.106555. Epub 2021 Mar 2. Leuk Res. 2021. PMID: 33705966 Free article.

5

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.

Kelly K, Swords R, Mahalingam D, Giles FJ. Kelly K, et al. Among authors: swords r. Leuk Lymphoma. 2010 Aug;51(8):1399-413. doi: 10.3109/10428194.2010.491135. Leuk Lymphoma. 2010. PMID: 20528247 Review.

6

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Giles FJ, O'Dwyer M, Swords R. Giles FJ, et al. Among authors: swords r. Leukemia. 2009 Oct;23(10):1698-707. doi: 10.1038/leu.2009.111. Epub 2009 May 28. Leukemia. 2009. PMID: 19474800 Review.

7

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.

Swords R, Freeman C, Giles F. Swords R, et al. Leukemia. 2012 Oct;26(10):2176-85. doi: 10.1038/leu.2012.114. Epub 2012 Apr 27. Leukemia. 2012. PMID: 22614177 Review.

8

Novel myelofibrosis treatment strategies: potential partners for combination therapies.

Stein BL, Swords R, Hochhaus A, Giles F. Stein BL, et al. Among authors: swords r. Leukemia. 2014 Nov;28(11):2139-47. doi: 10.1038/leu.2014.176. Epub 2014 Jun 3. Leukemia. 2014. PMID: 24888274 Review.

9

Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.

O'Dwyer ME, Swords R, Nagler A, McMullin MF, le Coutre PD, Langabeer SE, Alvarez-Iglesias A, Fan H, Woodman RC, Giles FJ, Conneally E. O'Dwyer ME, et al. Among authors: swords r. Leuk Res. 2014 Mar;38(3):310-5. doi: 10.1016/j.leukres.2013.11.016. Epub 2013 Dec 1. Leuk Res. 2014. PMID: 24333114 Clinical Trial.

10

Troxacitabine in acute leukemia.

Swords R, Giles F. Swords R, et al. Hematology. 2007 Jun;12(3):219-27. doi: 10.1080/10245330701406881. Hematology. 2007. PMID: 17558697 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page